Binimetinib

Binimetinib (MEK162) is an oral and selective MEK1/2 inhibitor. Binimetinib (MEK162) inhibits MEK with an IC50 of 12 nM.

Product Specifications

CAS Number

[606143-89-9]

Product Name Alternative

MEK162; ARRY-162; ARRY-438162

UNSPSC

12352005

Hazard Statement

H411

Target

Autophagy; MEK

Type

Reference compound

Related Pathways

Autophagy; MAPK/ERK Pathway

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/MEK162.html

Purity

99.92

Solubility

DMSO : 50 mg/mL (ultrasonic)

Smiles

BrC1=CC=C(C(F)=C1)NC2=C(C3=C(C=C2C(NOCCO)=O)N(C=N3)C)F

Molecular Formula

C17H15BrF2N4O3

Molecular Weight

441.23

Precautions

H411

References & Citations

[1]J Pheneger, et al. 2006, ACR Annual Scientific Meeting. Abst 794.|[2]Serra V, et al. RSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer. J Clin Invest, 2013, 123 (6), 2551-2563.|[3]Kiessling MK, et al. Mutant HRAS as novel target for MEK and mTOR inhibitors. Oncotarget. 2015 Dec 8;6 (39) :42183-96.|[4]Cheng H, et al. PIK3CA (H1047R) - and Her2-initiated mammary tumors escape PI3K dependency by compensatory activation of MEK-ERK signaling. Oncogene. 2016 Jun 9;35 (23) :2961-70.|[5]Seip K, et al. Fibroblast-induced switching to the mesenchymal-like phenotype and PI3K/mTOR signaling protects melanoma cells from BRAF inhibitors. Oncotarget. 2016 Apr 12;7 (15) :19997-20015.